Table 4 Clinical characteristics and functional outcome of adult patients with and without levamisole use .
| All adult patients with ADEM, n = 30 | Patients with levamisole use, n = 8 | p Value | |
|---|---|---|---|
| Age at onset (years) | 42.4 (16–90) | 53.1 (24–82) | 0.15 |
| Male | 11 (36.7) | 2 (25.0) | 0.43 |
| EDSS | 6.3–2.6 | 7.1–2.7 | 0.42 |
| Head MRI findings | |||
| Number of lesions | |||
| 1–3 | 5 (16.7) | 0 (0) | 0.40 |
| 4–6 | 3 (10.0) | 1 (12.5) | |
| >6 | 22 (73.3) | 7 (87.5) | |
| Gd‐enhanced lesions | 12 (40.0) | 5 (62.5) | 0.26 |
| CSF findings | |||
| Pleocytosis | 7 (23.3) | 2 (25.0) | 0.66 |
| L predominant | 6 (20.0) | 3 (37.5) | 0.70 |
| Protein (mg/dl; range) | 12 (40.0) | 1 (12.5) | 0.38 |
| Functional outcome | |||
| Rankin scale ⩾2 and death | 9 (30.0) | 1 (12.5) | 0.29 |
| Progress to MS | 1 (3.3) | 1 (12.5) | 0.39 |
| Follow‐up period (months) | 36.7 (20.2) | 36.9 (16.1) | 0.82 |
ADEM, acute‐disseminated encephalomyelitis; CSF, cerebrospinal fluid; DTPA, diethylenetriaminepenta‐acetic acid; EDSS, Expanded Disability Status Scale; Gd, gadolinium; MRI, magnetic resonance imaging; MS, multiple sclerosis.
Values are n (%) except age (mean (range)).